Strategy for Identifying Repurposed Drugs for the Treatment of Cerebral Cavernous Malformation

BACKGROUND: Cerebral cavernous malformation (CCM) is a hemorrhagic stroke disease affecting up to 0.5% of North Americans with no approved non-surgical treatment. A subset of patients have a hereditary form of the disease due primarily to loss-of-function mutations in KRIT1, CCM2, or PDCD10. We soug...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Circulation
Main Authors: Gibson, Christopher C., Zhu, Weiquan, Davis, Chadwick T., Bowman-Kirigin, Jay A., Chan, Aubrey C., Ling, Jing, Walker, Ashley E., Goitre, Luca, Monache, Simona Delle, Retta, Saverio Francesco, Shiu, Yan-Ting E., Grossmann, Allie H., Thomas, Kirk R., Donato, Anthony J., Lesniewski, Lisa A., Whitehead, Kevin J., Li, Dean Y.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4356181/
https://ncbi.nlm.nih.gov/pubmed/25486933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.114.010403
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados